Suppr超能文献

高剂量隔日使用皮质类固醇治疗全身型幼年类风湿性关节炎。

High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.

作者信息

Kimura Y, Fieldston E, Devries-Vandervlugt B, Li S, Imundo L

机构信息

Department of Pediatrics, Hackensack University Medical Center, NJ 07601, USA.

出版信息

J Rheumatol. 2000 Aug;27(8):2018-24.

Abstract

OBJECTIVE

To determine the safety and efficacy of high dose alternate day (qod) prednisone as therapy in acute systemic onset JRA (SOJRA).

METHODS

A retrospective chart review was performed of all active patients with SOJRA at our institutions who began high dose qod prednisone (n = 20; 9 male, 11 female; mean age of onset 6.5 yrs, range 1.2-18.6). Patients were followed for at least one year after initiation of high dose qod prednisone. Disease activity (fever, rash, active joint count, complete blood cell count, erythrocyte sedimentation rate, ESR) and possible side effects of treatment were assessed at each visit.

RESULTS

Within a mean of 2.1 months (range 1-5), systemic features (fever, rash, serositis, coagulopathy) in all patients had resolved and there was significant improvement in laboratory indices of disease activity. Doses ranged from 1 to 5.8 mg/kg qod (actual doses: 50-400 mg qod), with a mean of 3.2 mg/kg. No patient had to restart daily prednisone. The only major side effect was the development of mild cataracts in one patient. Height standard deviation scores (SDS) remained within normal range in all but 2 patients. Clinical improvement was maintained in all patients, as measured by lack of systemic symptoms, and decreased active joint count. Repeated measures of analysis of variance revealed significant improvement in all laboratory tests (white blood cell count, hemoglobin, platelet count, ESR) measured at 0, 6, and 12 months (p < 0.001). Nine of the 20 patients continued qod prednisone more than 12 months beyond the study period (mean 5.2 yrs, range 3-8). The only additional side effects were a vertebral crush fracture in one patient and possible avascular necrosis in another. Height SDS did not change significantly over the 3 year period after the initiation of qod prednisone (p > 0.05).

CONCLUSION

High dose qod prednisone appears to be effective in controlling the systemic features of SOJRA and was well tolerated. Side effects attributable to corticosteroids, including growth suppression, were minimal.

摘要

目的

确定高剂量隔日泼尼松作为急性全身型幼年特发性关节炎(SOJRA)治疗方法的安全性和有效性。

方法

对我院所有开始使用高剂量隔日泼尼松治疗的活动性SOJRA患者(n = 20;9名男性,11名女性;平均发病年龄6.5岁,范围1.2 - 18.6岁)进行回顾性病历审查。在开始高剂量隔日泼尼松治疗后,对患者进行至少一年的随访。每次就诊时评估疾病活动度(发热、皮疹、活动关节计数、全血细胞计数、红细胞沉降率,ESR)以及治疗可能产生的副作用。

结果

平均2.1个月(范围1 - 5个月)内,所有患者的全身症状(发热、皮疹、浆膜炎、凝血障碍)均得到缓解,疾病活动度的实验室指标有显著改善。剂量范围为每日每千克体重1至5.8毫克(实际剂量:每日50 - 400毫克),平均为每日每千克体重3.2毫克。没有患者需要重新开始每日服用泼尼松。唯一的主要副作用是1例患者出现轻度白内障。除2例患者外,所有患者的身高标准差评分(SDS)均保持在正常范围内。通过无全身症状以及活动关节计数减少来衡量,所有患者的临床症状均持续改善。重复测量方差分析显示,在0、6和12个月时测量的所有实验室检查指标(白细胞计数、血红蛋白、血小板计数、ESR)均有显著改善(p < 0.001)。20例患者中有9例在研究期后继续隔日服用泼尼松超过12个月(平均5.2年,范围3 - 8年)。仅出现另外2例副作用,1例患者发生椎体压缩性骨折,另1例可能出现无菌性坏死。在开始隔日服用泼尼松后的3年期间,身高SDS没有显著变化(p > 0.05)。

结论

高剂量隔日泼尼松似乎能有效控制SOJRA的全身症状,且耐受性良好。包括生长抑制在内的皮质类固醇所致副作用极小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验